Selected Publications

Lamble A, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard JD, Kovach AE, Wood BL, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN: Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv 7(4): 575-585, Feb 2023.

Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K & Barz Leahy A: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood 141(6): 609-619, Feb 2023.

Molina JC, Li Y, Otto WR, Miller TP, Getz KD, McCoubrey C, Ramos M, Krause E, Cao L, Gramatges MM, Rabin K, Scheurer M, Elgarten CW, Myers RM, Seif AE, Fisher BT, Shah NN & Aplenc R: Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer 70(1): e30062, Jan 2023.

Myers RM, Reilly AF, Szalda D.: Oncology. The Philadelphia Guide: Inpatient Pediatrics. Shah S, Catallozzi M, Ronan J (eds.). McGraw-Hill Education 3rd Edition, 2023 Notes: Chapter 21.

Myers RM*, Shah NN* & Pulsipher MA: How we use risk factors for success or failure of CD19 CAR T-cells to guide management of children/AYA with B-cell ALL. Blood 141(11): 1251-1264, Nov 2022 Notes: *Shared first authorship.

Myers RM & Frey N: Dual CAR T-cell for ALL (EXABS-134-ALL). Clin Lymphoma Myeloma Leuk 22(1): S42-S43, Oct 2022.

Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Barz Leahy A, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA & Teachey DT: Comprehensive serum profiling of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in B-cell ALL patients receiving CART19. Clin Cancer Res 28(17): 3804-3813, Sept 2022.

Hsieh EM, Myers RM, Yate B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard JD, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble A: Low rate of subsequent malignant neoplasms following CAR T-cell therapy. Blood Adv 6(17): 5222-5226, Sept 2022.

Talleur AC, Myers R, Annesley C & Shalabi H.: Chimeric antigen receptor T-cell therapy: Current status and clinical outcomes in pediatric hematologic malignancies. Hematol Oncol Clin North Am 36(4): 701-727, Aug 2022.

Li Y, Hwang WT, Maude SL, Teachey DT, Frey NV, Myers RM, Barz Leahy A, Liu H, Porter DL, Grupp SA & Shaw PA: Statistical considerations for analyses of time-to-event endpoints in oncology clinical trials: Illustrations with CAR-T immunotherapy studies. Clin Cancer Res 28(18): 3940-3949, Jul 2022.